Anne H Blaes1, G J van Londen2, Nicole Sandhu3, Amir Lerman3, Daniel A Duprez4. 1. University of Minnesota, 424 Delaware Street, S.E., MMC 480, Minneapolis, MN, 55455, USA. Blaes004@umn.edu. 2. University of Pittsburgh, Pittsburgh, PA, USA. 3. Mayo Clinic, Rochester, MN, USA. 4. University of Minnesota, 424 Delaware Street, S.E., MMC 480, Minneapolis, MN, 55455, USA.
Abstract
PURPOSE OF REVIEW: The purpose of this review is to summarize the current literature on estrogen and progesterone antagonists and their effects on the cardiovascular system. RECENT FINDINGS: Estrogen and progesterone antagonists reduce cancer-related recurrence and mortality in women with ER-positive breast cancer. Recent studies, however, suggest that women with early stage breast cancer are more likely to die of cardiovascular disease than recurrent breast cancer. Estrogen antagonists have been shown to reduce endothelial function, to increase lipid profiles and to alter body composition accelerating atherosclerotic changes. While clinical trial data demonstrates mixed results of the impact of estrogen antagonists on cardiovascular risk, there is a growing body of evidence that estrogen suppression and estrogen antagonists result in biologic effects on the endothelium, altering lipid profiles and accelerating the risk of atherosclerosis. Further longitudinal work however is needed.
PURPOSE OF REVIEW: The purpose of this review is to summarize the current literature on estrogen and progesterone antagonists and their effects on the cardiovascular system. RECENT FINDINGS: Estrogen and progesterone antagonists reduce cancer-related recurrence and mortality in women with ER-positive breast cancer. Recent studies, however, suggest that women with early stage breast cancer are more likely to die of cardiovascular disease than recurrent breast cancer. Estrogen antagonists have been shown to reduce endothelial function, to increase lipid profiles and to alter body composition accelerating atherosclerotic changes. While clinical trial data demonstrates mixed results of the impact of estrogen antagonists on cardiovascular risk, there is a growing body of evidence that estrogen suppression and estrogen antagonists result in biologic effects on the endothelium, altering lipid profiles and accelerating the risk of atherosclerosis. Further longitudinal work however is needed.
Entities:
Keywords:
Aromatase inhibitors; Breast cancer; Cardiovascular risk; Estrogen antagonists
Authors: Ronen Rubinshtein; Jeffrey T Kuvin; Morgan Soffler; Ryan J Lennon; Shahar Lavi; Rebecca E Nelson; Geralyn M Pumper; Lilach O Lerman; Amir Lerman Journal: Eur Heart J Date: 2010-02-24 Impact factor: 29.983
Authors: José J Fuster; Susan MacLauchlan; María A Zuriaga; Maya N Polackal; Allison C Ostriker; Raja Chakraborty; Chia-Ling Wu; Soichi Sano; Sujatha Muralidharan; Cristina Rius; Jacqueline Vuong; Sophia Jacob; Varsha Muralidhar; Avril A B Robertson; Matthew A Cooper; Vicente Andrés; Karen K Hirschi; Kathleen A Martin; Kenneth Walsh Journal: Science Date: 2017-01-19 Impact factor: 47.728
Authors: Sylvia Wassertheil-Smoller; Susan L Hendrix; Marian Limacher; Gerardo Heiss; Charles Kooperberg; Alison Baird; Theodore Kotchen; J David Curb; Henry Black; Jacques E Rossouw; Aaron Aragaki; Monika Safford; Evan Stein; Somchai Laowattana; W Jerry Mysiw Journal: JAMA Date: 2003-05-28 Impact factor: 56.272
Authors: Patrick T Bradshaw; June Stevens; Nikhil Khankari; Susan L Teitelbaum; Alfred I Neugut; Marilie D Gammon Journal: Epidemiology Date: 2016-01 Impact factor: 4.822
Authors: Cathleen M Rivera; Brandon R Grossardt; Deborah J Rhodes; Robert D Brown; Véronique L Roger; L Joseph Melton; Walter A Rocca Journal: Menopause Date: 2009 Jan-Feb Impact factor: 2.953
Authors: Jack Cuzick; Ivana Sestak; Michael Baum; Aman Buzdar; Anthony Howell; Mitch Dowsett; John F Forbes Journal: Lancet Oncol Date: 2010-11-17 Impact factor: 41.316